| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR3DL1 |
| Uniprot No | P43629 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 361-444aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSTSGT IDKLDIEFHL WCSNKKNAAV MDQEPAGNRT ANSEDSDEQD PEEVTYAQLD HCVFTQRKIT RPSQRPKTPP TDTILYTELP NAKPRSKVVS CP |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR3DL1重组蛋白的3篇参考文献示例(内容基于假设性研究，仅供参考)：
---
1. **标题**：*Structural Analysis of Recombinant KIR3DL1 Reveals Key Residues for HLA-B Binding*
**作者**：Smith A, et al.
**摘要**：通过大肠杆菌表达系统成功纯化重组KIR3DL1蛋白，结合X射线晶体学解析其三维结构，揭示了与HLA-Bw4表位结合的关键氨基酸位点。
2. **标题**：*Recombinant KIR3DL1 Fusion Protein Modulates NK Cell Activity in Chronic Viral Infection*
**作者**：Lee J, et al.
**摘要**：利用哺乳动物细胞表达KIR3DL1-Fc重组融合蛋白，体外实验证明其可阻断HIV感染模型中抑制性信号，增强NK细胞对感染细胞的清除能力。
3. **标题**：*Functional Impact of KIR3DL1 Allelic Variation Studied via Recombinant Protein Assays*
**作者**：Garcia R, et al.
**摘要**：通过重组表达不同KIR3DL1等位基因蛋白，发现特定变异体(如KIR3DL1*01502)与HLA-B的结合亲和力显著降低，影响NK细胞的功能调控。
---
注：以上文献为假设性示例，实际研究中建议通过PubMed或Google Scholar以关键词“KIR3DL1 recombinant protein”检索真实发表的论文。
KIR3DL1 is a member of the killer cell immunoglobulin-like receptor (KIR) family, primarily expressed on natural killer (NK) cells and a subset of T lymphocytes. As an inhibitory receptor, it plays a critical role in regulating NK cell activity by interacting with specific human leukocyte antigen (HLA) class I molecules, particularly those carrying the HLA-Bw4 epitope. This interaction delivers inhibitory signals to prevent NK cell-mediated destruction of healthy cells, ensuring immune tolerance while allowing detection of infected or malignant cells that downregulate HLA expression. KIR3DL1 exhibits extensive genetic polymorphism, influencing ligand-binding specificity and disease associations, including viral infection outcomes, autoimmune disorders, and hematopoietic stem cell transplantation compatibility.
Recombinant KIR3DL1 proteins are engineered in vitro using molecular cloning techniques, typically expressed in mammalian systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and structural fidelity. These proteins often comprise the extracellular domain fused to Fc tags or other solubility-enhancing motifs, enabling applications in structural studies, ligand interaction assays, and functional experiments. Researchers employ recombinant KIR3DL1 to map binding interfaces with HLA variants, characterize allelic variants' functional differences, and develop blockade strategies for immune modulation.
In therapeutic contexts, recombinant KIR3DL1 serves as a tool to investigate checkpoint inhibition in cancer immunotherapy and to engineer chimeric antigen receptors. Its study also sheds light on maternal-fetal tolerance mechanisms and viral immune evasion tactics. The protein's polymorphic nature and ligand specificity make it a focal point for personalized medicine approaches, particularly in transplantation matching and infectious disease susceptibility prediction. Ongoing research aims to leverage recombinant KIR3DL1 in diagnostic assays and bispecific molecule development, balancing NK cell activity for targeted disease interventions.
×
